AstraZeneca: new treatment for prostate cancer 'promising'
(CercleFinance.com) - AstraZeneca said a Phase II study evaluating its cancer cell killer Lynparza had promising results in metastatic castration-resistant prostate cancer, an aggressive form of the disease.
In the randomised, double-blinded, multi-centre trial, median radiologic progression-free survival (rPFS) was 13.8 months with Lynparza and abiraterone, compared to 8.2 months with standard of care abiraterone alone.
The results were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Lynparza is being jointly developed by AstraZeneca and US pharmaceutical giant Merck.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In the randomised, double-blinded, multi-centre trial, median radiologic progression-free survival (rPFS) was 13.8 months with Lynparza and abiraterone, compared to 8.2 months with standard of care abiraterone alone.
The results were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Lynparza is being jointly developed by AstraZeneca and US pharmaceutical giant Merck.
Copyright (c) 2018 CercleFinance.com. All rights reserved.